SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K/A
Amendment No. 1 to Current Report
Dated May 28, 2002
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 28, 2002
|
|
|
DEPOMED, INC. |
|
|
|||||
|
(Exact name of registrant as specified in its charter) |
|||||||||
|
|
|
|
|
|
|||||
|
California |
|
001-13111 |
|
94-3229046 |
|||||
|
(State of Incorporation or Organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|||||
|
|
|
|
|
|
|||||
|
1360 O’Brien Drive, Menlo Park, California |
|
94025 |
|||||||
|
(Address of principal executive offices) |
|
(Zip Code) |
|||||||
|
|
|
|
|
|
|||||
Registrant’s telephone no., including area code: (650) 462-5900
|
|
|
NOT APPLICABLE |
|
(Former name or former address, if changed since last report) |
Item 7. Financial Statements and Exhibits.
|
|
Exhibits. |
|
|
|
10.1 |
License and Development Agreement, dated as of May 28, 2002, between DepoMed, Inc. and Biovail Laboratories Incorporated.*† |
|
|
10.2 |
Stock Purchase Agreement, dated as of May 28, 2002, between DepoMed, Inc. and Biovail Laboratories Incorporated. |
|
|
* confidential treatment granted |
|
|
|
† previously filed |
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
DEPOMED, INC. |
|
|
|
|
|
/s/ John F. Hamilton |
|
|
John F. Hamilton |
|
|
Vice President - Finance and |
|
|
Chief Financial Officer |
Date: December 23, 2002
EXHIBIT INDEX
|
|
Exhibit |
|
|
|
10.1 |
License and Development Agreement, dated as of May 28, 2002, between DepoMed, Inc. and Biovail Laboratories Incorporated.*† |
|
|
10.2 |
Stock Purchase Agreement, dated as of May 28, 2002, between DepoMed, Inc. and Biovail Laboratories Incorporated. |
|
|
* confidential treatment granted |
|
|
|
† previously filed |
|